199 related articles for article (PubMed ID: 34980502)
1. Clinical outcomes, Kadish-INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastoma.
Lechner M; Takahashi Y; Turri-Zanoni M; Liu J; Counsell N; Hermsen M; Kaur RP; Zhao T; Ramanathan M; Schartinger VH; Emanuel O; Helman S; Varghese J; Dudas J; Riechelmann H; Sprung S; Haybaeck J; Howard D; Engel NW; Stewart S; Brooks L; Pickles JC; Jacques TS; Fenton TR; Williams L; Vaz FM; O'Flynn P; Stimpson P; Wang S; Hannan SA; Unadkat S; Hughes J; Dwivedi R; Forde CT; Randhawa P; Gane S; Joseph J; Andrews PJ; Royle G; Franchi A; Maragliano R; Battocchio S; Bewicke-Copley H; Pipinikas C; Webster A; Thirlwell C; Ho D; Teschendorff A; Zhu T; Steele CD; Pillay N; Vanhaesebroeck B; Mohyeldin A; Fernandez-Miranda J; Park KW; Le QT; West RB; Saade R; Manes RP; Omay SB; Vining EM; Judson BL; Yarbrough WG; Sansovini M; Silvia N; Grassi I; Bongiovanni A; Capper D; Schüller U; Thavaraj S; Sandison A; Surda P; Hopkins C; Ferrari M; Mattavelli D; Rampinelli V; Facchetti F; Nicolai P; Bossi P; Henriquez OA; Magliocca K; Solares CA; Wise SK; Llorente JL; Patel ZM; Nayak JV; Hwang PH; Lacy PD; Woods R; O'Neill JP; Jay A; Carnell D; Forster MD; Ishii M; London NR; Bell DM; Gallia GL; Castelnuovo P; Severi S; Lund VJ; Hanna EY
Eur J Cancer; 2022 Feb; 162():221-236. PubMed ID: 34980502
[TBL] [Abstract][Full Text] [Related]
2. Multicenter Survival Analysis and Application of an Olfactory Neuroblastoma Staging Modification Incorporating Hyams Grade.
Choby G; Geltzeiler M; Almeida JP; Champagne PO; Chan E; Ciporen J; Chaskes MB; Fernandez-Miranda J; Gardner P; Hwang P; Ji KSY; Kalyvas A; Kong KA; McMillan R; Nayak J; O'Byrne J; Patel C; Patel Z; Peris Celda M; Pinheiro-Neto C; Sanusi O; Snyderman C; Thorp BD; Van Gompel JJ; Young SC; Zenonos G; Zwagerman NT; Wang EW
JAMA Otolaryngol Head Neck Surg; 2023 Sep; 149(9):837-844. PubMed ID: 37535372
[TBL] [Abstract][Full Text] [Related]
3. SSTR2 Expression in Olfactory Neuroblastoma: Clinical and Therapeutic Implications.
Cracolici V; Wang EW; Gardner PA; Snyderman C; Gargano SM; Chiosea S; Singhi AD; Seethala RR
Head Neck Pathol; 2021 Dec; 15(4):1185-1191. PubMed ID: 33929681
[TBL] [Abstract][Full Text] [Related]
4. Comparing Kadish and Modified Dulguerov Staging Systems for Olfactory Neuroblastoma: An Individual Participant Data Meta-analysis.
Arnold MA; Farnoosh S; Gore MR
Otolaryngol Head Neck Surg; 2020 Sep; 163(3):418-427. PubMed ID: 32286935
[TBL] [Abstract][Full Text] [Related]
5. Treatment modalities and outcomes of olfactory neuroblastoma.
Song CM; Won TB; Lee CH; Kim DY; Rhee CS
Laryngoscope; 2012 Nov; 122(11):2389-95. PubMed ID: 23070733
[TBL] [Abstract][Full Text] [Related]
6. The clinicopathological spectrum of olfactory neuroblastoma and sinonasal neuroendocrine neoplasms: Refinements in diagnostic criteria and impact of multimodal treatments on survival.
Turri-Zanoni M; Maragliano R; Battaglia P; Giovannardi M; Antognoni P; Lombardi D; Morassi ML; Pasquini E; Tarchini P; Asioli S; Foschini MP; Sessa F; Nicolai P; Castelnuovo P; La Rosa S
Oral Oncol; 2017 Nov; 74():21-29. PubMed ID: 29103747
[TBL] [Abstract][Full Text] [Related]
7. Survival impact of postoperative radiotherapy in patients with olfactory neuroblastoma: 513 cases from the SEER database.
Duo GS; Feng JL; Zhang ZY; Wang LJ
Cancer Radiother; 2022 Sep; 26(5):663-669. PubMed ID: 35249817
[TBL] [Abstract][Full Text] [Related]
8. [Expression of SSTR2 and P-STAT3 in human olfactory neuroblastoma].
Zeng M; Cui Y; Wu C
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2010 Aug; 24(15):690-2. PubMed ID: 20942237
[TBL] [Abstract][Full Text] [Related]
9. Genetic and molecular alterations in olfactory neuroblastoma: implications for pathogenesis, prognosis and treatment.
Czapiewski P; Kunc M; Haybaeck J
Oncotarget; 2016 Aug; 7(32):52584-52596. PubMed ID: 27256979
[TBL] [Abstract][Full Text] [Related]
10. Treatment and outcome in 12 cases of olfactory neuroblastoma at Mexico´s National Cancer Institute: A retrospective clinical analysis and literature review.
Navarro-Fernández JO; Serrato-Avila JL; Hernández-Varela M; Tejada-Pineda MF; Hernández-Reséndiz RE; Monroy-Sosa A; Cacho-Díaz B; Herrera-Gómez Á; Reyes-Soto G
Cir Cir; 2020; 88(4):453-460. PubMed ID: 32567594
[TBL] [Abstract][Full Text] [Related]
11. Somatostatin receptor imaging of olfactory neuroblastoma.
Ramsay HA; Kairemo KJ; Jekunen AP
J Laryngol Otol; 1996 Dec; 110(12):1161-3. PubMed ID: 9015433
[TBL] [Abstract][Full Text] [Related]
12. Neuroradiological and Neuropathological Changes After 177Lu-Octreotate Peptide Receptor Radionuclide Therapy of Refractory Esthesioneuroblastoma.
Schneider JR; Shatzkes DR; Scharf SC; Tham TM; Kulason KO; Buteau FA; Del Prete M; Chakraborty S; Anderson TA; Asiry S; Beauregard JM; Langer DJ; Costantino PD; Boockvar JA
Oper Neurosurg (Hagerstown); 2018 Dec; 15(6):100-109. PubMed ID: 29554305
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Outcomes of Olfactory Neuroblastoma: MD Anderson Cancer Center Experience and Review of the Literature.
Abdelmeguid AS; Bell D; Roberts D; Ferrarotto R; Phan J; Su SY; Kupferman M; Raza S; DeMonte F; Hanna E
Laryngoscope; 2022 Feb; 132(2):290-297. PubMed ID: 34272876
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of Kadish staging in esthesioneuroblastoma: An analysis of the National Cancer Database.
Konuthula N; Iloreta AM; Miles B; Rhome R; Ozbek U; Genden EM; Posner M; Misiukiewicz K; Govindaraj S; Shrivastava R; Gupta V; Bakst RL
Head Neck; 2017 Oct; 39(10):1962-1968. PubMed ID: 28815831
[TBL] [Abstract][Full Text] [Related]
15. Patient characteristics of olfactory neuroblastoma: experience from a tertiary cancer centre 2000-2016 covering Eastern Denmark.
Gram SB; Grønhøj C; Mann H; Jakobsen KK; Kiss K; Bilde A; von Buchwald C
APMIS; 2018 Aug; 126(8):663-666. PubMed ID: 30168622
[TBL] [Abstract][Full Text] [Related]
16. Lymph node metastasis from olfactory neuroblastoma at presentation and as disease relapse: A systematic review and proportion meta-analysis of prevalence data and variables influencing regional control.
Tomasoni M; Marazzi E; Rampinelli V; Mattavelli D; Schreiber A; Deganello A; Piazza C
Head Neck; 2023 Jun; 45(6):1486-1496. PubMed ID: 36995898
[TBL] [Abstract][Full Text] [Related]
17. [Olfactory esthesioneuroblastoma: scintigraphic expression of somatostatin receptors].
García Vicente A; García Del Castillo E; Soriano Castrejón A; Alonso Farto J
Rev Esp Med Nucl; 1999 Oct; 18(5):367-70. PubMed ID: 10562667
[TBL] [Abstract][Full Text] [Related]
18. Outcome and prognostic factors in olfactory neuroblastoma: a rare cancer network study.
Ozsahin M; Gruber G; Olszyk O; Karakoyun-Celik O; Pehlivan B; Azria D; Roelandts M; Kaanders JH; Cengiz M; Krengli M; Matzinger O; Zouhair A
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):992-7. PubMed ID: 20231062
[TBL] [Abstract][Full Text] [Related]
19. The impact of multidisciplinary approaches on the outcomes of olfactory neuroblastoma treated with postoperative radiotherapy.
Tsutsumi Y; Omura K; Kijima Y; Kobayashi M; Fukasawa N; Takeda T; Ebihara T; Aoki S; Otori N; Kojima H; Aoki M
Cancer Med; 2024 Mar; 13(5):e6943. PubMed ID: 38497548
[TBL] [Abstract][Full Text] [Related]
20. Optimal treatment and prognostic factors for esthesioneuroblastoma: retrospective analysis of 187 Chinese patients.
Xiong L; Zeng XL; Guo CK; Liu AW; Huang L
BMC Cancer; 2017 Apr; 17(1):254. PubMed ID: 28399835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
